Trusted Resources: News & Events
Latest announcements and gatherings
Medicaid to Cover Endari for Sickle Cell Disease in the U.S.
Emmaus Life Sciences has reached an agreement with the Centers for Medicare and Medicaid Services that will allow coverage of Endari (L-glutamine oral powder) to reduce acute complications of sickle cell disease (SCD) in adults and children 5 years and older.
“This treatment is considered very important by many providers and patients because of its excellent safety profile and the evidence of effectiveness from the Phase III study that showed a reduction in acute chest syndrome, decreased occurrence of sickle crises and decreased frequency of hospitalizations in the Endari group compared to the placebo group,” Yutaka Niihara, MD, MPH, chairman and CEO of Emmaus, said in a press release. “Having the Medicaid Drug Rebate Program in place will make Endari more accessible to patients who need it most.”
+myBinderRelated Content
-
The clinical presentation, utilization, and outcome of individuals with sickle cell anaemia presenting to urban emer...Background: Sickle cell anaemia (SCA) i...
-
Increasing Appointment Attendance: A Vital Opportunity to Improve Health Outcomes for Those Living with Sickle Cell ...Sickle cell disease (SCD) affects approx...
-
Why selective marriage can’t help people with Sickle Cell disorder —ExpertSickle cell disorder is a distinct medic...
-
Sickle Cell + COVID-19 + Mental Health | The Sickle Cell PodcastThe Sickle Cell Podcast is an effort by ...
-
Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes...Interventions to assist reproductive hea...
-
Sickle Cell Treatment ‘Life-Changing’ for Brockton BrothersEmmanuel “Manny” Johnson, 21, of Bro...
-
Phase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer AnnouncesThe Phase 3 RESET trial testing the effe...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.